gene therapy groundbreaking

On January 22, 2024, the Dushu Lake Hospital affiliated with Soochow University and NeuExcell Therapeutics commenced an exploratory clinical study to evaluate the safety, tolerability, and preliminary effectiveness of NXL-004 injections in treating patients with malignant glioma.

The gene therapy drug NXL-004, central to the study, was developed by NeuExcell Therapeutics. Professor Huang Yulun of Dushu Lake Hospital, an expert in neurosurgery, is the principal investigator. The project also received congratulations from Patheon Biologics, a partner of NeuExcell Therapeutics, for its initiation.

The launch event was attended by Professor Huang Yulun and his team, NeuExcell Therapeutics co-founders Professor Chen Gong and Ms. Xu Jie, CEO Dr. Sheng Jian, and their R&D team, along with representatives from contract research organizations.

Professor Huang Yulun acknowledged the collaboration with NeuExcell Therapeutics, noting that NXL-004 has demonstrated promising efficacy and safety in preclinical studies. Professor Chen Gong expressed appreciation for the collaborative efforts and high hopes for the drug, developed using neural transcription factors, targeting malignant gliomas.

The meeting covered the development background, product details, and research methodology, emphasizing adherence to Good Clinical Practice (GCP) and relevant legal regulations to protect participant rights and privacy, aiming for quality research results.

Dr. Sheng Jian, CEO of NeuExcell Therapeutics, expressed gratitude for the support from Dushu Lake Hospital and anticipated the prompt commencement of patient enrollment and the potential positive impact on patients, hopeful for the clinical trial’s success.

The article also highlights the high mortality rate of malignant gliomas, particularly glioblastomas (GBM), and the current limitations in their treatment, which includes surgery, radiation therapy, and chemotherapy. It mentions the inevitability of recurrence in these patients and the need for better treatment options.

NXL-004, based on Professor Chen Gong’s team’s innovative cell transdifferentiation technology, is presented as an innovative gene therapy drug for gliomas. It received Orphan Drug Designation from the FDA in December 2023 for treating malignant brain gliomas, the first such designation for an AAV gene therapy product in this category.

The initiation of this study signifies the entry of NXL-004 into clinical development, offering potential new treatment options for patients with malignant gliomas.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.